CIAM
SLN icon

Caitong International Asset Management’s Silence Therapeutics SLN Stock Holding History

Caitong International Asset Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$450 Buy
41
+38
+1,267% +$267 ﹤0.01% 1762
2026
Q1 		$16 Buy
+3
New +$17 ﹤0.01% 2096

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Caitong International Asset Management's SLN Position: Q2 2026 in Review

Caitong International Asset Management increased its Silence Therapeutics (SLN) stake by 1,267% in Q2 2026, buying an estimated $267 and bringing the position to 41 shares worth $450. The position accounts for ﹤0.01% of the portfolio, ranked #1762.

Caitong International Asset Management first reported a position in SLN in Q1 2026 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Caitong International Asset Management held 41 shares of Silence Therapeutics worth $450 as of Q2 2026.
  • Caitong International Asset Management bought 38 Silence Therapeutics shares in Q2 2026, an estimated $267.
  • Silence Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1762 holding.
  • Caitong International Asset Management first reported a position in Silence Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.